000K  utf8
1100  $c2023
1500  eng
2050  urn:nbn:de:gbv:8:3-2025-00032-2
2051  10.1024/1662-9647/a000311
3000  Pauli, Philipp
3010  Bartsch, Thorsten
3010  Berg, Daniela Dagmar Denise
3010  Goetz, Katja
3010  Hertrampf, Katrin
3010  Philippen, Sarah
3010  Rogge, Annette
4000  Attitudes and Viewpoints Toward Prevention Trials in Alzheimer’s Disease$hHogrefe Publishing Group  [Pauli, Philipp]
4030  $nHogrefe Publishing Group
4209  Alzheimer’s disease (AD) prevention studies use biomarkers to determine risk in asymptomatic study participants. This involves multifaceted implications. Determinants regarding participation in these trials are therefore of particular relevance. We used semistructured individual interviews to interview uninvolved persons (n = 10), relatives of Alzheimer’s patients (n = 10), and patients with mild cognitive impairment (n = 5) and analyzed the interviews using qualitative content analysis according to Mayring. We discovered various factors to be positive motivations for participation; the most significant inhibiting factor was concern about negative psychological effects. These motivations and concerns should be specifically addressed in the study design of AD prevention trials. The fears and concerns expressed highlight the importance of a good methodological and ethical framework to increase participant acceptance.
4950  https://doi.org/10.1024/1662-9647/a000311$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2025-00032-2$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/macau_mods_00005553
5051  610
5550  Alzheimer’s disease
5550  barriers
5550  prevention studies
5550  qualitative study
5550  risk disclosure